Colchicine reduces the degree of inflammation in COVID-19 patients

Abstract

COVID-19 increases vulnerability for populations living in regions significantly impacted by the adverse effects of climate change. There is currently no definitive treatment for COVID-19. Colchicine is a drug that can reduce the severity of COVID-19 by inhibiting the NLRP3 inflammasome. This study aims to determine the effect of colchicine administration on the high-sensitivity C-reactive protein (HsCRP) and Neutrophil to Lymphocyte Ratio (NLR) levels in COVID-19 patients. This study was conducted at the UNS Hospital in February-March 2021. The inclusion criteria were moderate-grade COVID-19 patients. HsCRP and NLR examinations were carried out before and after giving the treatment. The treatment group received 2x0.5 mg colchicine for 7 days and standard therapy, while the control group received placebo and standard therapy. Statistical test using paired t-test and independent t-test. P is significant if p is less than 0.05. The study subjects were 40 patients, with 20 patients in the control group and 20 in the treatment group. There was a decrease in NLR and HsCRP levels in the treatment group before therapy (NLR = 7.89 + 3.45; HsCRP = 5.41 + 3.24 mg/dL) compared to after therapy (NLR = 3.59 + 2.25; HsCRP = 1.41 + 1.13 mg/dL) with p = 0.001. Colchicine reduces the degree of NLR and HsCRP in COVID-19 patients.

Neuthropil-to-Lymphocyte Ratio Correlation with Pneumonia Severity Index in COVID-19 Patients

“…r=0.205 and p = 0.168, which was statistically significant. This study has different results from the study of Imran M et al, which reported that patients with severe COVID-19 have a high NLR and that NLR is an independent risk factor for severe infection (Imran et al, 2021;Prabowo & Apriningsih, 2021). Li et al (2020) suggest that NLR can be a good biomarker for forecasting the severity of illness in COVID-19 patients.…”

Moringa Oleifera Extract Decreases Interleukin 6 Levels and Disease Activity in Rheumatoid Arthritis Patients

“…This increase in IL-6 levels indicates an increase in the severity of RA disease and vice versa (9,17) . Excessive ROS production will cause oxidative stress, stimulating the active transcription factor NF-ĸB (Nuclear factor kappa B) (18) as a marker of acute inflammation, increasing levels of oxidants expressing proinflammatory agents, including TNF-α. Acute inflammation that is not appropriately handled, prolonged, and repeated will cause tissue necrosis (19) .…”

“…The inflammatory process plays a significant role in the pathogenesis of RA. Proinflammatory markers such as c-reactive protein (CRP), interleukin-6 (IL 6) (7) , tumor necrosis factor (TNF-α), and IL-10 (8) were very high in synovial fluid and serum of RA patients. Studies have shown that inflammatory markers such as hs-CRP, IL-6, IL-10, and TNF-α were significantly increased in RA patients compared to controls and correlated with disease activity (9) .…”

Moringa Oleifera Extract Decreases Interleukin 6 Levels and Disease Activity in Rheumatoid Arthritis Patients

“…Excessive ROS production will cause oxidative stress, stimulating the active transcription factor NF-ĸB (Nuclear factor kappa B) (18) as a marker of acute inflammation, increasing levels of oxidants expressing proinflammatory agents, including TNF-α. Acute inflammation that is not appropriately handled, prolonged, and repeated will cause tissue necrosis (19) .…”